Physician profile
Victoria E Grudzinski
NPI 1124330048
$3,727.13
in general payments reported to CMS, 2019-2025
24 companies · $1,107 in 2025
The $1,107 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $150 · 2023: $1,293 · 2024: $1,177 · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,545 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,544.86 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $868.15 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $402.46 | 2022-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $369.96 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $355.74 | 2022-2025 | |
| Pfizer INC. | $239.74 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.43 | 2023-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $193.57 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Edwards Lifesciences Corporation | $180.65 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amgen INC. | $174.24 | 2023-2025 | Repatha, Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $153.38 | 2023-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.51 | 2025 | Xifaxan |
| Abbott Laboratories | $64.30 | 2022-2025 | Freestyle Libre 3 |
| Seqirus USA INC | $63.27 | 2023-2025 | Fluad, Flucelvax, Fluad Quadrivalent |
| Merck Sharp & Dohme LLC | $59.33 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Paratek Pharmaceuticals, INC. | $46.33 | 2023-2024 | Nuzyra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $36.73 | 2023 | Xarelto |
| Amphastar Pharmaceuticals, INC. | $35.83 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $33.53 | 2023-2024 | Farxiga, Breztri |
| Biogen, INC. | $28.72 | 2025 | Zurzuvae |
| E.R. Squibb & Sons, L.L.C. | $19.57 | 2023 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $19.42 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $19.00 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $14.39 | 2023 | |
| Dexcom, INC. | $12.88 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Grudzinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.